Skip to main content
Journal cover image

The role of immune checkpoint inhibition in the treatment of ovarian cancer.

Publication ,  Journal Article
Gaillard, SL; Secord, AA; Monk, B
Published in: Gynecol Oncol Res Pract
2016

The introduction of immune checkpoint inhibitors has revolutionized treatment of multiple cancers and has bolstered interest in this treatment approach. So far, emerging clinical data show limited clinical efficacy of these agents in ovarian cancer with objective response rates of 10-15% with some durable responses. In this review, we present emerging clinical data of completed trials of immune checkpoint inhibitors and review ongoing studies. In addition we examine the current knowledge of the tumor microenvironment of ovarian cancers with a focus on the significance of PD-L1 expression and tumor-infiltrating lymphocytes on predicting response to immune checkpoint blockade. We evaluate approaches to improve treatment outcomes through the use of predictive biomarkers and patient selection. Finally, we review management considerations including immune related adverse events and response criteria.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Gynecol Oncol Res Pract

DOI

ISSN

2053-6844

Publication Date

2016

Volume

3

Start / End Page

11

Location

England

Related Subject Headings

  • 3215 Reproductive medicine
  • 3211 Oncology and carcinogenesis
  • 1117 Public Health and Health Services
  • 1114 Paediatrics and Reproductive Medicine
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Gaillard, S. L., Secord, A. A., & Monk, B. (2016). The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecol Oncol Res Pract, 3, 11. https://doi.org/10.1186/s40661-016-0033-6
Gaillard, Stéphanie L., Angeles A. Secord, and Bradley Monk. “The role of immune checkpoint inhibition in the treatment of ovarian cancer.Gynecol Oncol Res Pract 3 (2016): 11. https://doi.org/10.1186/s40661-016-0033-6.
Gaillard SL, Secord AA, Monk B. The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecol Oncol Res Pract. 2016;3:11.
Gaillard, Stéphanie L., et al. “The role of immune checkpoint inhibition in the treatment of ovarian cancer.Gynecol Oncol Res Pract, vol. 3, 2016, p. 11. Pubmed, doi:10.1186/s40661-016-0033-6.
Gaillard SL, Secord AA, Monk B. The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecol Oncol Res Pract. 2016;3:11.
Journal cover image

Published In

Gynecol Oncol Res Pract

DOI

ISSN

2053-6844

Publication Date

2016

Volume

3

Start / End Page

11

Location

England

Related Subject Headings

  • 3215 Reproductive medicine
  • 3211 Oncology and carcinogenesis
  • 1117 Public Health and Health Services
  • 1114 Paediatrics and Reproductive Medicine
  • 1112 Oncology and Carcinogenesis